Table 1.
Demographics and REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) Scores
| IPDa | LRRK2-PDb | NMCc | NC-Fd | Controle | |
|---|---|---|---|---|---|
|
| |||||
| n | 144 | 142 | 117 | 93 | 40 |
| Women % | 35.4%cde | 45.8%ce | 59.8%ab | 50.5%ae | 72.5%abd |
| Age years | 64.9 ± 11.3cde | 67.2 ± 9.8cd | 53.3 ± 15.9 abe | 52.8 ± 18.5 abe | 69.8 ± 10.6acd |
| UPDRS-III | 20.1 ± 11.8cde | 21.1 ± 13.1cde | 2.5 ± 3.5ab | 2.5 ± 3.5ab | 2.1 ± 3.4ab |
| Age onset | 58.0 ± 10.9 | 57.4 ± 11.0 | - | - | - |
| PD Duration years | 7.4 ± 7.5b | 10.0 ± 7.1a | - | - | - |
| RBDSQ score median (IQR) | 4.0 (2.0–7.0)cde | 3.0 (2.0–5.0)cde | 2.0 (1.0–3.0)ab | 2.0 (1.0–4.0)ab | 2.0 (1.0–4.0)ab |
| RBD+ % | 30.6%bcde | 19.7%ac | 6.0%abd | 20.4%ac | 15.0%a |
| Odds Ratios for Abnormal RBDSQ Scores Among
| |||
|---|---|---|---|
| All Groups ** | |||
| n = 536 | OR | 95% CI | P |
| Age | 1.01 | .99–1.02 | 0.56 |
| Sex (Women) | 0.64 | .41–1.01 | 0.06 |
| Site (NY) | 1.57 | .97–2.54 | 0.07 |
| Group: | |||
| Control (ref) | --- | --- | --- |
| IPD | 2.75 | .03–7.35 | 0.04 |
| LRRK2-PD | 1.50 | .56–4.04 | 0.42 |
| NMC | 0.46 | .14–1.54 | 0.21 |
| NC-F | 1.89 | .65–5.51 | 0.25 |
| Further group comparisons* | |||
| IPD vs. LRRK2-PD | 1.83 | .05–3.18 | 0.03 |
| NMC vs. LRRK2-PD | 0.31 | .13–0.75 | 0.01 |
| NC-F vs. LRRK2-PD | 0.80 | .40–1.59 | 0.52 |
| NMC vs. NC-F | 0.25 | .10–0.61 | <0.01 |
| Odds Ratios for RBDSQ Restricted to PD Groups
| |||
|---|---|---|---|
| n = 275 | OR | 95% CI | P |
| IPD vs. LRRK2-PD | 2.38 | .29–4.38 | <0.01 |
| Age | 1.01 | .99–1.04 | 0.34 |
| Sex (Women) | 0.54 | .29–1.00 | 0.05 |
| Site (NY) | 1.37 | .75–2.52 | 0.31 |
| Duration | 1.08 | .03–1.14 | <0.01 |
| UPDRS-III | 0.99 | .97–1.02 | 0.20 |
Additional group comparisons were deduced from the main model; Values provided are number (%) or mean ± SD, as appropriate, unless otherwise stated; Superscripts denote significant differences from the superscripted group (p<0.05); ORs from GEE models adjusted for age, site (NY vs. Israel), gender and family membership Definitions: LRRK2-PD=LRRK2 G2019S mutation carriers with PD; IPD=idiopathic PD; NMC=LRRK2 mutation carriers without PD; NC-F=non-carrier family members; UPDRS-III=Unified Parkinson Disease Rating Scale Motor Score; RBDSQ=REM Sleep Behavior Disorder Screening Questionnaire; RBD+=total RBDSQ score ≥ 5 (non-PD) and total RBDSQ score ≥ 6 (PD).
In post-hoc analysis using the main GEE model to assess site differences, all differences from the main model were maintained when limited to participants from either NY or TA, except that NMC from NY were not different from LRRK2-PD (OR=0.34, p=0.07) or NC-F (OR=0.30, p=0.06) and, although the magnitude of the OR was maintained, in TA the odds of RBD was not significantly reduced in LRRK2-PD vs. IPD (OR=0.73, p=0.49).